Kylie E. C. Ainslie

Kylie E. C. Ainslie

Auto-generated profile, based on publicly available information

Kylie E. C. Ainslie

Centre for infectious disease control, National institute for public health and the environment (RIVM), Bilthoven, the Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2020 in Science
Verified
Journal Article
Open access
PDF file
PWPatrick G. T. Walker
Patrick G. T. Walker
CWCharles Whittaker
Charles Whittaker
OWOliver J. Watson
Oliver J. Watson
MBMarc Baguelin
Marc Baguelin
PWPeter Winskill
Peter Winskill
AGAzra C. Ghani
Azra C. Ghani
Global prospects for COVID-19 control: Lower-income countries have recognized the potential impact of coronavirus disease 2019 (COVID-19) from observing ongoing epidemics. Many have intervened quickly and early with measures to slow viral transmission, which may partly explain the low rates observed so far in these countries. Walker et al. calibrated a global model with country-specific data (see the Perspective by Metcalf et al. ). Despite the potentially protective effects of younger demographics, the closer intergenerational contact, limitations on health care facilities, and frequency of comorbidities in lower-income countries require sustained nonpharmaceutical interventions (NPIs) to avoid overwhelming health care capacity. As a result of strict NPIs, the protective effects of immunity will be reduced, and it will be important to improve testing capacity. Ensuring equitable provision of oxygen and—when they are ready—pharmaceutical interventions should be a global priority. Science , this issue p. 413 ; see also p. 368

17 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
PNPierre Nouvellet
Pierre Nouvellet
SBSangeeta Bhatia
Sangeeta Bhatia
ACAnne Cori
Anne Cori
KAKylie E. C. Ainslie
Kylie E. C. Ainslie
MBMarc Baguelin
Marc Baguelin
CDChristl A Donnelly
Christl A Donnelly
In response to the COVID-19 pandemic, countries have sought to control SARS-CoV-2 transmission by restricting population movement through social distancing interventions, thus reducing the number of contacts. Mobility data represent an important proxy measure of social distancing, and here, we characterise the relationship between transmission and mobility for 52 countries around the world. Transmission significantly decreased with the initial reduction in mobility in 73% of the countries analysed, but we found evidence of decoupling of transmission and mobility following the relaxation of strict control measures for 80% of countries. For the majority of countries, mobility explained a substantial proportion of the variation in transmissibility (median adjusted R-squared: 48%, interquartile range - IQR - across countries [27–77%]). Where a change in the relationship occurred, predictive ability decreased after the relaxation; from a median adjusted R-squared of 74% (IQR across countries [49–91%]) pre-relaxation, to a median adjusted R-squared of 30% (IQR across countries [12–48%]) post-relaxation. In countries with a clear relationship between mobility and transmission both before and after strict control measures were relaxed, mobility was associated with lower transmission rates after control measures were relaxed indicating that the beneficial effects of ongoing social distancing behaviours were substantial.

10 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
HWHelen Ward
Helen Ward
CAChristina Atchison
Christina Atchison
MWMatthew Whitaker
Matthew Whitaker
KAKylie E. C. Ainslie
Kylie E. C. Ainslie
JEJoshua Elliott
Joshua Elliott
PEPaul Elliott
Paul Elliott
England has experienced a large outbreak of SARS-CoV-2, disproportionately affecting people from disadvantaged and ethnic minority communities. It is unclear how much of this excess is due to differences in exposure associated with structural inequalities. Here, we report from the REal-time Assessment of Community Transmission-2 (REACT-2) national study of over 100,000 people. After adjusting for test characteristics and re-weighting to the population, overall antibody prevalence is 6.0% (95% CI: 5.8-6.1). An estimated 3.4 million people had developed antibodies to SARS-CoV-2 by mid-July 2020. Prevalence is two- to three-fold higher among health and care workers compared with non-essential workers, and in people of Black or South Asian than white ethnicity, while age- and sex-specific infection fatality ratios are similar across ethnicities. Our results indicate that higher hospitalisation and mortality from COVID-19 in minority ethnic groups may reflect higher rates of infection rather than differential experience of disease or care.

14 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
HWHelen Ward
Helen Ward
CAChristina J Atchison
Christina J Atchison
MWMatthew Whitaker
Matthew Whitaker
KAKylie E. C. Ainslie
Kylie E. C. Ainslie
JEJoshua Elliott
Joshua Elliott
PEPaul Elliott
Paul Elliott
Background: England, UK has experienced a large outbreak of SARS-CoV-2 infection. As in USA and elsewhere, disadvantaged communities have been disproportionately affected. Methods: National REal-time Assessment of Community Transmission-2 (REACT-2) prevalence study using a self-administered lateral flow immunoassay (LFIA) test for IgG among a random population sample of 100,000 adults over 18 years in England, 20 June to 13 July 2020. Results: Data were available for 109,076 participants, yielding 5,544 IgG positive results; adjusted (for test performance) and re-weighted (for sampling) prevalence was 6.0% (95% Cl: 5.8, 6.1). Highest prevalence was in London (13.0% [12.3, 13.6]), among people of Black or Asian (mainly South Asian) ethnicity (17.3% [15.8, 19.1] and 11.9% [11.0, 12.8] respectively) and those aged 18-24 years (7.9% [7.3, 8.5]). Adjusted odds ratio for care home workers with client-facing roles was 3.1 (2.5, 3.8) compared with non-essential workers. One third (32.2%, [31.0-33.4]) of antibody positive individuals reported no symptoms. Among symptomatic cases, most (78.8%) reported symptoms during the peak of the epidemic in England in March (31.3%) and April (47.5%) 2020. We estimate that 3.36 million (3.21, 3.51) people have been infected with SARS-CoV-2 in England to end June 2020, with an overall infection fatality ratio (IFR) of 0.90% (0.86, 0.94); age-specific IFR was similar among people of different ethnicities. Conclusion: The SARS-CoV-2 pandemic in England disproportionately affected ethnic minority groups and health and care home workers. The higher risk of infection in minority ethnic groups may explain their increased risk of hospitalisation and mortality from COVID-19.

28 May 2021 in Science
Verified
Journal Article
Open access
PDF file
SRSteven Riley
Steven Riley
KAKylie E. C. Ainslie
Kylie E. C. Ainslie
OEOliver Eales
Oliver Eales
CWCaroline E. Walters
Caroline E. Walters
HWHaowei Wang
Haowei Wang
PEPaul Elliott
Paul Elliott
Community virus surveillance: Even highly effective vaccines will not save us from the need to monitor severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) activity, perhaps for years to come. Public health institutions will need early warning of any uptick in cases to prepare and deploy interventions as required. Riley et al. developed a community-wide program that was designed to detect resurgence at low prevalence and has been used to track SARS-CoV-2 virus across England. In the four rounds of sampling from May to September 2020, almost 600,000 people representative of all communities were monitored. The results revealed the greatest prevalence among 18- to 24-year-olds, with increasing incidence among older age groups and elevated odds of infection among some communities. This testing approach offers a model for the type of real-time, country-wide population-based surveillance work that needs to be conducted to monitor SARS-CoV-2. Science , abf0874, this issue p. 990

27 October 2020 in medRxiv
Verified
Preprint
Open access
PDF file
HWHelen Ward
Helen Ward
GCGraham Cooke
Graham Cooke
CAChristina Atchison
Christina Atchison
MWMatthew Whitaker
Matthew Whitaker
JEJoshua Elliott
Joshua Elliott
PEPaul Elliott
Paul Elliott
Background The prevalence and persistence of antibodies following a peak SARS-CoV-2 infection provides insights into its spread in the community, the likelihood of reinfection and potential for some level of population immunity. Methods Prevalence of antibody positivity in England, UK (REACT2) with three cross-sectional surveys between late June and September 2020. 365104 adults used a self-administered lateral flow immunoassay (LFIA) test for IgG. A laboratory comparison of LFIA results to neutralization activity in panel of sera was performed. Results There were 17,576 positive tests over the three rounds. Antibody prevalence, adjusted for test characteristics and weighted to the adult population of England, declined from 6.0% [5.8, 6.1], to 4.8% [4.7, 5.0] and 4.4% [4.3, 4.5], a fall of 26.5% [-29.0, −23.8] over the three months of the study. There was a decline between rounds 1 and 3 in all age groups, with the highest prevalence of a positive result and smallest overall decline in positivity in the youngest age group (18-24 years: −14.9% [-21.6, −8.1]), and lowest prevalence and largest decline in the oldest group (75+ years: −39.0% [-50.8, −27.2]); there was no change in antibody positivity between rounds 1 and 3 in healthcare workers (+3.45% [-5.7, +12.7]). The decline from rounds 1 to 3 was largest in those who did not report a history of COVID-19, (−64.0% [-75.6, −52.3]), compared to −22.3% ([-27.0, −17.7]) in those with SARS-CoV-2 infection confirmed on PCR. Discussion These findings provide evidence of variable waning in antibody positivity over time such that, at the start of the second wave of infection in England, only 4.4% of adults had detectable IgG antibodies using an LFIA. Antibody positivity was greater in those who reported a positive PCR and lower in older people and those with asymptomatic infection. These data suggest the possibility of decreasing population immunity and increasing risk of reinfection as detectable antibodies decline in the population.